Thermo Fisher Scientific has announced the expansion of its GlobalAccess Sequencing programme to include laboratories working in oncology. Originally introduced to accelerate multi-institutional-led studies focused on SARS-CoV-2, the expanded programme now provides support to labs facing significant constraints as a result of the global pandemic by offering faster access to comprehensive, single-day molecular profiling of tumor tissue on Thermo Fisher’s Ion Torrent Genexus System.
“We know that the COVID-19 pandemic has interrupted the way laboratories function on a daily basis. For some, it has deeply impacted their ability to serve customers in circumstances where time is of the essence,” said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “At this unprecedented time, sustaining the momentum in oncology is paramount. Extending the benefits of GlobalAccess to this community is a natural extension of our mission to enable our customers to help make the world healthier.”
Read more about this news here.
